MarketCapExport financials
Natus Medical Incorporated (NTUS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Natus Medical Incorporated Income Statement 2021-2008 | NTUS
Brief overview of income trends at Natus Medical Incorporated
The figures are compared over a five-year interval. The revenue attributed to Natus Medical Incorporated moved from 382 million dollars to 473 million dollars between the two endpoints. The total change was +24%, with a CAGR of approximately 4.4%. Sales changed only slightly and remained broadly flat.
Gross profit was 235 million dollars at the start and 274 million dollars at the end of the period (+16.5%). Gross profit as a share of revenue changed from 61.5% to 57.8%. The margin decline reflects a less favorable sales-and-cost structure.
The five-year EBITDA result moved by −28.1%: from 72.1 million dollars to 51.9 million dollars. EBITDA lagged revenue, showing weaker operating momentum. Comparing the endpoints gives EBITDA margins of 18.9% and 11%. The business retained less EBITDA from each unit of revenue.
The five-year change in net income was −69.1%: from $42.6 million to $13.2 million. The decline reduces the quality of the financial trajectory.
Over the period, capitalization shifted from 1.1 billion dollars to 799 million dollars (−29.3%). The market became more cautious about the prospects of the business.
Conclusion
The current trajectory does not yet confirm a sustainable recovery. The most visible risks are lower investor confidence, a declining EBITDA margin and weak sales momentum. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement Natus Medical Incorporated
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
799 M | 673 M | 1.11 B | 1.13 B | 1.24 B | 1.13 B | 1.55 B | 1.14 B | 675 M | 324 M | 269 M | - | - | - |
Shares |
33.7 M | 33.6 M | 33.7 M | 33.1 M | 32.6 M | 32.5 M | 32.3 M | 31.5 M | 30 M | 29 M | 28.6 M | 28.1 K | 27.7 M | - |
Historical Prices |
23.7 | 20 | 33 | 34 | 38.2 | 34.8 | 48 | 36 | 22.5 | 11.2 | 9.43 | - | - | - |
Net Income |
13.2 M | -16.6 M | -15.7 M | -22.9 M | -20.3 M | 42.6 M | 37.9 M | 32.5 M | 23.1 M | 3.82 M | -11.2 M | 11.9 M | 11.4 M | - |
Revenue |
473 M | 416 M | 495 M | 531 M | 501 M | 382 M | 376 M | 356 M | 344 M | 292 M | 233 M | 218 M | 166 M | - |
Cost of Revenue |
- | - | 197 M | 218 M | 213 M | 145 M | 145 M | 138 M | 139 M | 129 M | 102 M | 88.6 M | 66.1 M | - |
Gross Profit |
274 M | 217 M | 292 M | 304 M | 281 M | 235 M | 228 M | 214 M | 202 M | 163 M | 131 M | 130 M | 100 M | - |
Operating Income |
23.8 M | -20.2 M | -15.7 M | -24.6 M | 8.72 M | 55.3 M | 53.5 M | 45.9 M | 34.7 M | 5.11 M | -10.3 M | 17.9 M | 15.3 M | - |
Interest Expense |
1.87 M | 3.66 M | 4.94 M | 6.79 M | 5.08 M | 430 K | 352 K | 438 K | 1.68 M | 489 K | 268 K | 128 K | - | - |
EBITDA |
51.9 M | 7.92 M | 15.1 M | 9.3 M | 38.8 M | 72.1 M | 69.5 M | 57.6 M | 47.5 M | 17.7 M | -141 K | 27 M | 23.2 M | - |
Operating Expenses |
250 M | 237 M | 307 M | 329 M | 272 M | 180 M | 174 M | 169 M | 168 M | 158 M | 142 M | 112 M | 85 M | - |
General and Administrative Expenses |
52.8 M | 49.1 M | 59.6 M | 70.6 M | 74.4 M | 50.9 M | 46.4 M | 45.4 M | 43.4 M | 51 M | 33 M | 35.8 M | 23 M | - |
All numbers in USD currency
Quarterly Income Statement Natus Medical Incorporated
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | - | - | 34.1 M | 34.2 M | 33.6 M | 33.6 M | 33.6 M | 33.9 M | 33.8 M | 33.8 M | 33.8 M | 34.1 M | 33.7 M | 33.6 M | 33.6 M | 33.8 M | 33.3 M | 32.9 M | 32.8 M | 33.1 M | 32.6 M | 32.5 M | 32.5 M | 32.9 M | 32.4 M | 32.4 M | 32.6 M | 33.2 M | 32.4 M | 32.3 M | 32.1 M | 32.6 M | 31.6 M | 31.4 M | 31.1 M | 31.4 M | 30.1 M | 29.7 K | 29.6 K | 30.1 M | 29.1 K | 28.9 K | 28.9 M | 29.4 M | 28.6 M | 28.4 M | 28.3 M |
Net Income |
- | - | - | 1.9 M | - | 5.57 M | 3.46 M | 2.4 M | - | -9.32 M | -8.9 M | -3.6 M | - | 8.46 M | 4.19 M | -30 M | - | -5.58 M | -2.58 M | -3.15 M | - | -8.51 M | -5.03 M | 348 K | - | 13.3 M | 10.5 M | 8.54 M | - | 10.9 M | 9.85 M | 8.6 M | - | 7.79 M | 7.74 M | 6.25 M | - | 6.29 M | 4.02 M | 3.44 M | - | -1.95 M | 445 K | 358 K | - | 154 K | 2.36 M | 3.1 M |
Revenue |
- | - | - | 120 M | - | 114 M | 116 M | 115 M | - | 103 M | 84.8 M | 109 M | - | 123 M | 126 M | 115 M | - | 131 M | 131 M | 129 M | - | 123 M | 122 M | 125 M | - | 90.9 M | 96 M | 87.3 M | - | 94.6 M | 91.9 M | 89.4 M | - | 89.9 M | 86.3 M | 85.6 M | - | 85.4 M | 82.2 M | 85.8 M | - | 80.7 M | 61 M | 59.5 M | - | 51.3 M | 58.1 M | 59.1 M |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | 48.7 M | 52.2 M | 46.4 M | - | 51.6 M | 52.9 M | 55.4 M | - | 47.1 M | 54.6 M | 56.9 M | - | 32.2 M | 37.9 M | 32.5 M | - | 35.5 M | 33.8 M | 35.1 M | - | 34.3 M | 35.3 M | 35.7 M | - | 34.1 M | 33.9 M | 36.6 M | - | 36.5 M | 26.8 M | 26 M | - | 23.8 M | 25 M | 24.4 M |
Gross Profit |
- | - | - | 65.4 M | - | 67.7 M | 66.4 M | 66.5 M | - | 47.5 M | 40.6 M | 62.8 M | - | 73 M | 71.6 M | 66.6 M | - | 77.1 M | 75 M | 71.7 M | - | 74.2 M | 66.1 M | 66.7 M | - | 58.1 M | 57.5 M | 54.3 M | - | 58.4 M | 57.4 M | 53.6 M | - | 55.5 M | 51 M | 49.9 M | - | 51.3 M | 48.4 M | 49.2 M | - | 44.3 M | 34.2 M | 33.5 M | - | 27.6 M | 33.1 M | 34.7 M |
Operating Income |
- | - | - | 4.18 M | - | 8.54 M | 6.01 M | 4.52 M | - | -9.94 M | -12 M | -3.23 M | - | 8.09 M | 7.5 M | -37.6 M | - | -2.91 M | -3.79 M | -2.73 M | - | 8.54 M | -6.28 M | 1.4 M | - | 15.2 M | 13.9 M | 11.2 M | - | 16.1 M | 14 M | 13.3 M | - | 12.8 M | 10.3 M | 8.68 M | - | 9.14 M | 6.16 M | 4.86 M | - | -4.85 M | 805 K | 161 K | - | -1.04 M | 3.16 M | 5.04 M |
Interest Expense |
- | - | - | 267 K | - | 332 K | 556 K | 766 K | - | 1.11 M | 976 K | 717 K | - | 1.17 M | 1.47 M | 1.53 M | - | 1.65 M | 1.64 M | 1.96 M | - | 1.04 M | 1.28 M | 980 K | - | 223 K | 97 K | 31 K | - | - | - | 1 K | - | 104 K | 120 K | 264 K | - | 138 K | 469 K | 477 K | - | 215 K | 8 K | 8 K | - | 47 K | 64 K | - |
EBITDA |
- | - | - | 10.9 M | - | 29.9 M | 20.5 M | 11.8 M | - | 11.1 M | 1.64 M | 3.76 M | - | 31 M | 22.9 M | -29.9 M | - | 22.7 M | 12.9 M | 5.19 M | - | 29.4 M | 7.54 M | 8.15 M | - | 28.1 M | 22.3 M | 15.4 M | - | 27.4 M | 21.2 M | 16.3 M | - | 21.3 M | 15.9 M | 12 M | - | 18.7 M | 12.5 M | 7.99 M | - | -3.85 M | 2.1 M | 3.1 M | - | 5.73 M | 7.65 M | 7.59 M |
Operating Expenses |
- | - | - | 61.2 M | - | 59.2 M | 60.4 M | 62 M | - | 57.5 M | 52.6 M | 66 M | - | 64.9 M | 64.1 M | 104 M | - | 80 M | 78.8 M | 74.4 M | - | 65.7 M | 72.4 M | 65.3 M | - | 42.9 M | 43.5 M | 43 M | - | 42.3 M | 43.4 M | 40.3 M | - | 42.8 M | 40.7 M | 41.2 M | - | 42.2 M | 42.2 M | 44.4 M | - | 49.1 M | 33.4 M | 33.3 M | - | 28.6 M | 29.9 M | 29.7 M |
General and Administrative Expenses |
- | - | - | 12.8 M | - | 12.9 M | 12.6 M | 14.9 M | - | 12.4 M | 11.2 M | 13.2 M | - | 15.1 M | 12.7 M | 16.3 M | - | 15.8 M | 23.7 M | 17.4 M | - | 17.3 M | 24.2 M | 16 M | - | 12.8 M | 11.9 M | 12.5 M | - | 10 M | 11.7 M | 11.6 M | - | 14.7 M | 10.8 M | 12.3 M | - | 14.3 M | 11.8 M | 14 M | - | 18.8 M | 10.9 M | 9.53 M | - | 7.81 M | 7.99 M | 9.03 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Natus Medical Incorporated (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Conformis
CFMS
|
- | - | $ 16.4 M |  USA |
 |
Bruker Corporation
BRKR
|
$ 64.0 | 7.26 % | $ 9.72 B | USA |
 |
Boston Scientific Corporation
BSX
|
$ 44.68 | 0.06 % | $ 66.1 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
$ 8.7 | 0.06 % | $ 634 M |  Israel |
 |
ClearPoint Neuro
CLPT
|
$ 14.61 | 13.03 % | $ 414 M | USA |
 |
CONMED Corporation
CNMD
|
$ 45.18 | 3.31 % | $ 1.4 B | USA |
 |
Cytosorbents Corporation
CTSO
|
$ 4.3 | 1.63 % | $ 268 M | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
Delcath Systems
DCTH
|
$ 16.08 | 0.75 % | $ 576 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Electromed
ELMD
|
$ 27.86 | 1.05 % | $ 230 M | USA |
 |
Establishment Labs Holdings
ESTA
|
$ 65.58 | 3.69 % | $ 1.94 B |  Costa-rica |
 |
Edwards Lifesciences Corporation
EW
|
$ 85.73 | 0.32 % | $ 50.1 B | USA |
 |
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M |  Britain |
 |
AdaptHealth Corp.
AHCO
|
$ 5.57 | 0.43 % | $ 753 M | USA |
 |
Helius Medical Technologies
HSDT
|
$ 2.9 | 0.69 % | $ 63.9 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
$ 15.88 | 2.25 % | $ 1.22 B | USA |
 |
Inogen
INGN
|
$ 5.23 | 2.75 % | $ 139 M | USA |
 |
InMode Ltd.
INMD
|
$ 14.19 | 0.21 % | $ 917 M | Israel |
 |
Inspire Medical Systems
INSP
|
$ 68.81 | 0.59 % | $ 2.02 B | USA |
 |
Neovasc
NVCN
|
- | - | $ 111 M |  Canada |
 |
IRIDEX Corporation
IRIX
|
$ 0.63 | 2.51 % | $ 10.7 M | USA |
 |
IRadimed Corporation
IRMD
|
$ 85.2 | 0.08 % | $ 1.08 B | USA |
 |
AxoGen
AXGN
|
$ 43.32 | 0.48 % | $ 1.99 B | USA |
 |
Align Technology
ALGN
|
$ 145.63 | 4.36 % | $ 10.6 B | USA |
|
LENSAR
LNSR
|
$ 7.08 | 0.28 % | $ 84.7 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | USA |
 |
Medtronic PLC
MDT
|
$ 88.51 | 0.32 % | $ 113 B | USA |
 |
MiMedx Group
MDXG
|
$ 4.71 | 0.1 % | $ 696 M | USA |
 |
Surgalign Holdings
SRGA
|
- | -32.98 % | $ 1.68 M | USA |
 |
ShockWave Medical
SWAV
|
- | - | $ 12.3 B | USA |
 |
Myomo
MYO
|
$ 1.67 | 1.83 % | $ 69.9 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.66 | 0.45 % | $ 42.8 M | Israel |
 |
InspireMD
NSPR
|
$ 0.7 | 0.37 % | $ 45 M | Israel |
 |
Orthofix Medical
OFIX
|
$ 9.16 | 0.11 % | $ 363 M |  Curacao |
 |
Outset Medical
OM
|
$ 3.13 | 1.29 % | $ 47.6 K | USA |
 |
Insulet Corporation
PODD
|
$ 135.78 | 0.01 % | $ 9.55 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 5.6 | 1.66 % | $ 169 M | Canada |
 |
Titan Medical
TMDI
|
- | -26.32 % | $ 19.6 M | Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.18 | 0.63 % | $ 136 M | USA |
 |
AVITA Medical
RCEL
|
$ 11.58 | 5.75 % | $ 323 M |  Australia |
 |
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | USA |
 |
Apyx Medical Corporation
APYX
|
$ 2.83 | 1.37 % | $ 116 M | USA |
 |
Sintx Technologies
SINT
|
$ 1.87 | 5.06 % | $ 5.19 M | USA |
 |
Accuray Incorporated
ARAY
|
$ 0.22 | 0.4 % | $ 27 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 26.68 | 0.02 % | $ 23.1 B | Britain |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |